Health & WellnessTech
CannabisPeople of Color
Aphios Pharma
Aphios Pharma is developing cannabis-based therapeutics for anxiety, pain, opioid use disorder & MS
Woburn,
MA
Investment type:
Equity
(SAFE)
Target raise:
$50,000
- $1,000,000
Minimum investment:
$250
$250
End date:
Mar 01, 2022
Mar 01, 2022
ended
Share
Highlights
- Green biotech developing sustained release nanoencapsulated cannabinoids for highly unmet chronic medical needs
- ESG opportunity addressing a $4B market for cancer pain, $5B for opioid use disorder and $40B for Multiple Sclerosis
- Aphios has spent $44 million to date on developing enabling drug manufacturing and drug delivery technologies
- Including $7.9M in peer-reviewed grants from National Cancer Institute, National Institute on Drug Abuse and NCCIH, NIH
Our Story
Aphios® Pharma LLC is developing FDA-approved, cannabis and hemp-based drugs for treating highly unmet central and peripheral nervous system disorders of chemotherapy induced peripheral neuropathic pain (CIPNP), opioid addiction and Multiple Sclerosis that are only partially and anecdotally addressed by medical marijuana.
Our Ambition
We will be a company with commercial sales of cannabis-based, FDA-approved drugs for cancer pain, opioid addiction and Multiple Sclerosis.